AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32274665 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced symptoms (vaginal dryness, sleep disturbances, bone or joint pain) at 6 months
Number of subjects: 0
Study 32274665 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression scores at 6 months
Number of subjects: 0
Study 32274665 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at randomization
Number of subjects: 0
Study 33188417 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat (WGW) intervention (98 g/d)
Number of subjects: 37
Study 33188417 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW) intervention (98 g/d)
Number of subjects: 37
Study 32566949 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial nail matricectomy (PNM) using CO2 laser
Number of subjects: 127
Study 32566949 — intervention group
Group type: COMPARATOR
Intervention: Lateral nail fold excision (LNFE)
Number of subjects: 127
Study 33789268 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF with polysulfone haemodialyser
Number of subjects: 22
Study 33789268 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF with polymethylmethacrylate membrane
Number of subjects: 22
Study 33789268 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF with cellulose triacetate membrane
Number of subjects: 22
Study 33789268 — intervention group
Group type: COMPARATOR
Intervention: High-flux HD
Number of subjects: 22
Study 33002645 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus real rTMS
Number of subjects: 50
Study 33002645 — intervention group
Group type: COMPARATOR
Intervention: CT plus placebo rTMS
Number of subjects: 50
Study 33883461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination BP therapy with perindopril and indapamide
Number of subjects: 14682
Study 32873460 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + cognitive remediation
Number of subjects: 146
Study 32873460 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 146
Study 35630107 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam−remifentanil (RR) group
Number of subjects: 90
Study 35630107 — intervention group
Group type: COMPARATOR
Intervention: Propofol−remifentanil (PR) group
Number of subjects: 90
Study 34227314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble HQSAR model using DB‐210 stationary phase; FD set to 'donor/acceptor atoms (DA)' and FS set to 1-9.
Number of subjects: 34
Study 34227314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble HQSAR model using HP‐Innowax stationary phase; FD set to 'DA' and FS set to 4-7.
Number of subjects: 34
Study 34227314 — intervention group
Group type: COMPARATOR
Intervention: Individual HQSAR model using DB‐210 stationary phase.
Number of subjects: 34
Study 34227314 — intervention group
Group type: COMPARATOR
Intervention: Individual HQSAR model using HP‐Innowax stationary phase.
Number of subjects: 34
Study 32802868 — intervention group
Group type: EXPERIMENTAL
Intervention: SL implants (implants with an augmented depth of the threads)
Number of subjects: 14
Study 32802868 — intervention group
Group type: COMPARATOR
Intervention: SY implants (implants with standard threads)
Number of subjects: 14
Study 32802868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SL and SY implants
Number of subjects: 14
Study 35652298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast immobilization for 4 weeks
Number of subjects: 50
Study 35652298 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization for 6 weeks
Number of subjects: 50
Study 32384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic patient-controlled analgesia (PCA) or regional analgesic techniques
Number of subjects: 900
Study 32384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 900
Study 32384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of postoperative pain
Number of subjects: 900
Study 32384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Recovery (QoR)
Number of subjects: 900
Study 32384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational improvements
Number of subjects: 900
Study 35970671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 25 mL of bupivacaine plus 0.5 μg/kg of dexmedetomidine
Number of subjects: 130
Study 35970671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 130
Study 35970671 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous analgesia with a 0.7 μg/kg dexmedetomidine bolus and a 0.3 μg/kg infusion
Number of subjects: 130
Study 35970671 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous analgesia
Number of subjects: 130
Study 34185376 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent gesture training
Number of subjects: 100
Study 34185376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 33260146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR)
Number of subjects: 8
Study 33260146 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 8
Study 33025616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek extract (FHE) 250 mg × 2/day for 42 days
Number of subjects: 48
Study 33025616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33025616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek extract (FHE)
Number of subjects: 48
Study 35470518 — intervention group
Group type: EXPERIMENTAL
Intervention: Wonders & Worries intervention
Number of subjects: 60
Study 35470518 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 33852919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w (Mw) 0.3 mL/d intradermally for 3 days
Number of subjects: 202
Study 33852919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 33852919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w (Mw)
Number of subjects: 202
Study 33852919 — intervention group
Group type: COMPARATOR
Intervention: Mycobacterium w (Mw) and Placebo
Number of subjects: 202
Study 33991552 — intervention group
Group type: EXPERIMENTAL
Intervention: Frova Intubating Catheter (IC)
Number of subjects: 49
Study 33991552 — intervention group
Group type: COMPARATOR
Intervention: McGrath Videolaryngoscope (VL)
Number of subjects: 49
Study 33843705 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture control training using a virtual reality (VR) program
Number of subjects: 20
Study 33843705 — intervention group
Group type: COMPARATOR
Intervention: Arm reach training in the sitting position (Control)
Number of subjects: 20
Study 35639720 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1gm BD intravenously for three days, followed by oral citicoline 1gm BD for 39 days.
Number of subjects: 0
Study 35639720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100ml intravenous normal saline for three days, followed by multivitamin tablet BD for 39 days).
Number of subjects: 0
Study 35639720 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 0
Study 33559293 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (3D CNN) model
Number of subjects: 237
Study 33559293 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentations of tumor by two radiologists
Number of subjects: 237
Study 33147257 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF post-ASCT
Number of subjects: 111
Study 33147257 — intervention group
Group type: COMPARATOR
Intervention: Avoided G-CSF post-ASCT
Number of subjects: 111
Study 33147257 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoided G-CSF and added corticosteroid prophylaxis post-ASCT
Number of subjects: 111
Study 33147257 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF avoidance plus corticosteroids
Number of subjects: 111
Study 35380875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 42
Study 35380875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Bathing (AB)
Number of subjects: 42
Study 35380875 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CON)
Number of subjects: 42
Study 34266998 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) + Coronally advanced flap (CAF)
Number of subjects: 10
Study 34266998 — intervention group
Group type: COMPARATOR
Intervention: De‐epithelialized connective tissue graft (DeCTG) + Coronally advanced flap (CAF)
Number of subjects: 10
Study 33425825 — intervention group
Group type: EXPERIMENTAL
Intervention: wecoach web-application
Number of subjects: 0
Study 36116756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based resilience training (active intervention)
Number of subjects: 706
Study 36116756 — intervention group
Group type: COMPARATOR
Intervention: Passive web-based psychoeducation about chronic stress and burnout (control)
Number of subjects: 706
Study 36116756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (up to 3 sequential interventions based on non-response)
Number of subjects: 706
Study 33751297 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (Group A)
Number of subjects: 42
Study 33751297 — intervention group
Group type: COMPARATOR
Intervention: Early loading (Group B)
Number of subjects: 42
Study 33751297 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (50 implants)
Number of subjects: 42
Study 33751297 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of radiographic bone levels
Number of subjects: 42
Study 35508680 — intervention group
Group type: COMPARATOR
Intervention: DBS switched off (STIM OFF)
Number of subjects: 13
Study 35508680 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional stimulation with 60 µs (oDBS60)
Number of subjects: 13
Study 35508680 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional stimulation with 30 µs (oDBS30)
Number of subjects: 13
Study 35508680 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional stimulation at the best segment with 60 µs (dDBS60)
Number of subjects: 13
Study 36384755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 298
Study 32134114 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A virus vaccine (HA‐L)
Number of subjects: 1297
Study 36093705 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 46
Study 36093705 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 46
Study 34838132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thyroxine for at least 12 hours
Number of subjects: 800
Study 34838132 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 800
Study 32424949 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine continuous rate infusion (CRI) at 1 mg/kg/hr for 2, 4, and 6 hours after an initial bolus of 0.5 mg/kg
Number of subjects: 0
Study 32424949 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine continuous rate infusion (CRI)
Number of subjects: 0
Study 35260787 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (COMT inhibitor)
Number of subjects: 35
Study 35260787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 33001210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 0.01%
Number of subjects: 220
Study 33001210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 35468752 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoura treatment
Number of subjects: 30
Study 35468752 — intervention group
Group type: COMPARATOR
Intervention: Custom‐Q treatment
Number of subjects: 30
Study 33531449 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl gel
Number of subjects: 52
Study 33531449 — intervention group
Group type: COMPARATOR
Intervention: NaOCl solution
Number of subjects: 52
Study 34241629 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg orally once daily on days 1 to 21) plus SOX (S‐1: 40‐60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles
Number of subjects: 48
Study 34241629 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus SOX
Number of subjects: 48
Study 32445850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 63
Study 32445850 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 63
Study 32445850 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 63
Study 35075738 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Guilt Reduction (TrIGR)
Number of subjects: 145
Study 35075738 — intervention group
Group type: COMPARATOR
Intervention: Supportive Care Therapy (SCT)
Number of subjects: 145
Study 35075738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 145
Study 34925003 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) prescriptions
Number of subjects: 0
Study 34925003 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug group
Number of subjects: 0
Study 34925003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group
Number of subjects: 0
Study 34925003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group
Number of subjects: 0
Study 32127340 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 50
Study 32127340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35492074 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 35492074 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine + Ketamine (Mor + Ket)
Number of subjects: 0
Study 35492074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32731825 — intervention group
Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 72
Study 32731825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless 3D-printed TKA
Number of subjects: 72
Study 32731825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless TKA
Number of subjects: 72
Study 35496368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus completed 10 min before anesthesia induction followed by an infusion at 2.0 mg/kg/h)
Number of subjects: 60
Study 35496368 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (volume-matched at the same infusion rate)
Number of subjects: 60
Study 32105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g/d) given from the diagnosis of primary infection up to amniocentesis
Number of subjects: 90
Study 32105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valaciclovir (8 g/d) given to pregnant women with a mildly symptomatic fetus
Number of subjects: 90
Study 32105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir given to symptomatic neonates
Number of subjects: 90
Study 32397821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pika Pamoja (treatment)
Number of subjects: 10
Study 32397821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 36905345 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Number of subjects: 401
Study 36905345 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.7 mg
Number of subjects: 401
Study 36905345 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 401
Study 32568128 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional active trunk training exercises using the Space Balance 3D system
Number of subjects: 24
Study 32568128 — intervention group
Group type: COMPARATOR
Intervention: General trunk training exercises
Number of subjects: 24
Study 32347695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector planning
Number of subjects: 114
Study 32347695 — intervention group
Group type: COMPARATOR
Intervention: Manifest refraction (MR) planning
Number of subjects: 114
Study 35952313 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored lifestyle intervention (n = 60)
Number of subjects: 120
Study 35952313 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical education (n = 60)
Number of subjects: 120
Study 33854132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (NMDA receptor antagonist)
Number of subjects: 16
Study 33854132 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (AMPA receptor antagonist)
Number of subjects: 16
Study 33854132 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (L-type voltage-gated calcium channel blocker)
Number of subjects: 16
Study 33854132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32544109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 40
Study 35893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal flap on the flap side of the neo-ostium
Number of subjects: 12
Study 35893422 — intervention group
Group type: COMPARATOR
Intervention: No mucosal flap on the non-flap side of the neo-ostium
Number of subjects: 12
Study 35893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative SNOT-22 score
Number of subjects: 12
Study 35893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative UPSIT score
Number of subjects: 12
Study 32028996 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mM Tris‐HCl (pH 7.5) extraction followed by 20% TCA‐acetone precipitation
Number of subjects: 3
Study 32028996 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications during protein washing, re‐solubilization in rehydration buffer, and isoelectric focusing (IEF)
Number of subjects: 3
Study 32028996 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry identification of spots from the 2‐DE gel of D. hirsuta
Number of subjects: 3
Study 34237668 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology for 12 weeks
Number of subjects: 48
Study 34237668 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and follow-up (Control)
Number of subjects: 48
Study 33157912 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based rational emotive behavior programme (V-REBP)
Number of subjects: 56
Study 33157912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 35792064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg Q3W for up to 35 cycles + chemotherapy: paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5)
Number of subjects: 57
Study 35792064 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (same chemotherapy regimen)
Number of subjects: 57
Study 33849844 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg
Number of subjects: 60
Study 33849844 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 60
Study 32357944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-aflatoxin pre-blended porridge flour (maize and groundnut in a 4:1 ratio) and low-aflatoxin groundnut flour, provided to the intervention group starting at 6 months of age.
Number of subjects: 3120
Study 32357944 — intervention group
Group type: COMPARATOR
Intervention: Low-aflatoxin pre-blended porridge flour and low-aflatoxin groundnut flour promoted through education but acquired by the household in the control group.
Number of subjects: 3120
Study 32357944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (low-aflatoxin diet)
Number of subjects: 3120
Study 32357944 — intervention group
Group type: COMPARATOR
Intervention: Control group (education on the same porridge mix and groundnut flour)
Number of subjects: 3120
Study 34343623 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lateral quadratus lumborum block (40 mL, ropivacaine 0.25%)
Number of subjects: 46
Study 34343623 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 46
Study 34343623 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lateral quadratus lumborum block
Number of subjects: 46
Study 32940786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) at fast tempo (120% of normal tempo)
Number of subjects: 60
Study 32940786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) at normal tempo
Number of subjects: 60
Study 32940786 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrically healthy individuals
Number of subjects: 60
Study 32932051 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMP test with ½kg weight
Number of subjects: 70
Study 32932051 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMP test with 1kg weight
Number of subjects: 70
Study 32932051 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMP test with 1½kg weight
Number of subjects: 70
Study 32932051 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMP test overall
Number of subjects: 70
Study 35020888 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 0
Study 33955088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-based speed of processing training (VSOP)
Number of subjects: 0
Study 33955088 — intervention group
Group type: COMPARATOR
Intervention: Mental leisure activities (MLA)
Number of subjects: 0
Study 35083545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory
Number of subjects: 92
Study 35083545 — intervention group
Group type: COMPARATOR
Intervention: Standard care (systematic questioning approach)
Number of subjects: 92
Study 33636401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser stimulation (1064-nm wavelength laser, power density: 250 mW/cm2)
Number of subjects: 68
Study 33636401 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 68
Study 32694245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 178
Study 35071605 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 37
Study 35071605 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 37